⇚ Regimen ENHERTU® - for Breast Cancer Medical Name Single Agent ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Ultralow Metastatic Breast Cancer Cycles Given N/A Delivery Phases N/A Special Instructions As monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. Treatment given until disease progression or unacceptable toxicity. Must be monitored closely for INTERSTITIAL LUNG DISEASE References Curigliano G, et al. J Clin Oncol. 2024 - VIEW External References https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.17_suppl.LBA1000 - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration ENHERTU® (fam-trastuzumab deruxtecan-nxki) IV 5.4 mg/kg D1 q21 D5W 100 mL 90 mins